Photosensitive antibody-phuorophore conjugates

Abstract

The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm<-2>. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.

Description

[0001] Cross References to Related Applications

[0002] This application is a continuation-in-part of U.S. Application No. 13 / 180,111, filed July 11, 2011, which claims priority to U.S. Provisional Application No. 61 / 363,079, filed July 9, 2010, both incorporated by reference way into this article. technical field

[0003] The present application relates to antibody-IR700 conjugates and methods of using antibody-IR700 conjugates to kill cells specifically bound to said antibodies after irradiation with infrared (NIR) light. Also provided are devices incorporating NIR light emitting diodes (LEDs) that can also be used with the conjugates and methods of the present disclosure. Background technique

[0004] In 2007, about 13% of all human deaths were caused by cancer. Although there are some therapies against cancer, there remains a need for therapies that effectively kill tumor cells while sparing non-cancerous cells.

[0005] To minimize the side effects of conventional c...

Images